Evolus (EOLS) Earnings Date & Reports

Key Takeaways

• Second-quarter 2026 total net revenue reached $84.1 million, up 21% year over year and slightly ahead of the roughly $82 million consensus estimate.
• The company delivered its third consecutive quarter of positive adjusted EBITDA at $4.7 million, compared with a loss of $7.9 million a year earlier.
• Full-year 2026 revenue guidance was raised to a range of $330 million to $337 million, with adjusted gross margin guidance lifted to 67.0% to 67.5%.
• GAAP net loss narrowed to $0.12 per share from $0.27 per share in the prior-year period.
• Gross margin benefited by roughly 120 basis points from a one-time tariff refund recognized during the quarter.

Earnings Context and Why It Matters

Evolus, Inc. (EOLS), a "performance beauty" company best known for its Jeuveau (Nuceiva) neurotoxin and the Evolysse line of hyaluronic acid (HA) fillers, has spent recent quarters repositioning itself as a diversified, multi-product aesthetics business. This quarterly earnings report matters because it offers the clearest signal yet of whether that pivot is producing sustainable profitability, not just top-line growth. Following an expense-reduction program in 2025, management has emphasized operating leverage, and the second quarter tests that thesis against rising investments in international expansion and new product launches. For investors, the results carry implications for the company's long-term 2028 financial targets and its ability to fund growth without diluting shareholders.

Reported Results

Evolus reported second-quarter 2026 total net revenue of $84.1 million, a 21% increase over the $69.4 million recorded in the second quarter of 2025. The figure included $75.2 million of global toxin revenue and $8.9 million from injectable hyaluronic acid (HA) gels, reflecting double-digit toxin growth across U.S. and international markets as well as continued momentum in the Evolysse portfolio.

Gross profit margin was 68.0%, while adjusted gross margin, which excludes amortization of intangible assets, came in at 69.0%. Both figures benefited by approximately 120 basis points from a tariff refund recognized during the quarter. GAAP operating expenses were $61.7 million, while non-GAAP operating expenses were $53.3 million, up sequentially as the company invested in customer education, marketing, and the European launch of Estyme.

The company reported a GAAP loss from operations of $4.5 million, narrowing from a $10.2 million loss a year earlier. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) was positive at $4.7 million, a $12.6 million year-over-year improvement and the third consecutive quarter of positive adjusted EBITDA. GAAP net loss was $8.1 million, or $0.12 per share, compared with a $17.1 million loss, or $0.27 per share, in the prior-year period.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a useful companion for monitoring earnings-driven movers like Evolus. Explore the AI Screener to surface new ideas aligned with your strategy.

Market Reaction and Investor Sentiment

Investor sentiment heading into the report was shaped by management's promise of sustainable profitability, and the third straight quarter of positive adjusted EBITDA supported that narrative. The company's decision to raise its full-year revenue and gross margin guidance signaled confidence in the second half, while the announcement of new strategic agreements — including the U.S. licensing of Profhilo and expanded Estyme rights into Canada, Australia, and New Zealand — broadened the long-term growth story. At the same time, a wider-than-expected GAAP net loss and a sequential decline in cash and cash equivalents to $45.2 million tempered enthusiasm, underscoring that meaningful GAAP profitability remains a work in progress.

Forward Outlook and Key Factors to Monitor

Following this earnings report, investors will be watching whether Evolus can sustain its revenue momentum while protecting margins. The company raised full-year 2026 revenue guidance to $330 million to $337 million and adjusted gross margin to 67.0% to 67.5%, while reaffirming a low- to mid-single digit adjusted EBITDA margin for the year.

Several catalysts are worth monitoring. The anticipated U.S. approval of Evolysse Sculpt in the fourth quarter of 2026 — with no revenue contribution assumed in current guidance — represents a potential upside driver into 2027. The European commercialization of the Estyme gel collection and the early ramp of the Profhilo skin-quality agreement, which management estimates could exceed $100 million in peak annual revenue, are also key growth pillars.

On the cost side, tariff policy remains a variable. Evolysse is subject to a 10% tariff as a medical device, and management is prudently relocating about one year's worth of Jeuveau inventory into the U.S. Investors will also track operating leverage, as non-GAAP operating expense growth is expected to stay in a modest 1% to 3% range for the full year.

Finally, the company's balance sheet merits attention. With $45.2 million in cash and access to additional non-dilutive capacity, management has stated it does not anticipate further equity financing — but disciplined execution against its profitability targets will remain central to that claim as it scales internationally.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations